TR199700723T1 - Uyu�turucu (ila�) ba��ml�l���ndan zarar g�ren hastalar�n tedavisi i�in melatonin kullan�m�. - Google Patents

Uyu�turucu (ila�) ba��ml�l���ndan zarar g�ren hastalar�n tedavisi i�in melatonin kullan�m�.

Info

Publication number
TR199700723T1
TR199700723T1 TR97/00723T TR9700723T TR199700723T1 TR 199700723 T1 TR199700723 T1 TR 199700723T1 TR 97/00723 T TR97/00723 T TR 97/00723T TR 9700723 T TR9700723 T TR 9700723T TR 199700723 T1 TR199700723 T1 TR 199700723T1
Authority
TR
Turkey
Prior art keywords
drug
melatonin
treatment
addiction
diagnosed
Prior art date
Application number
TR97/00723T
Other languages
English (en)
Turkish (tr)
Inventor
Nava Zisapel
Original Assignee
Neurim Pharmaceuticals (1991) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,535 external-priority patent/US6469044B1/en
Application filed by Neurim Pharmaceuticals (1991) Ltd. filed Critical Neurim Pharmaceuticals (1991) Ltd.
Publication of TR199700723T1 publication Critical patent/TR199700723T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TR97/00723T 1995-02-01 1996-01-29 Uyu�turucu (ila�) ba��ml�l���ndan zarar g�ren hastalar�n tedavisi i�in melatonin kullan�m�. TR199700723T1 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
EP95303853A EP0724878B1 (fr) 1995-02-01 1995-06-06 Utilisation de la mélatonine pour traiter les patients souffrant d'une dépendance vis à vis d'une drogue

Publications (1)

Publication Number Publication Date
TR199700723T1 true TR199700723T1 (xx) 1998-02-21

Family

ID=26140195

Family Applications (1)

Application Number Title Priority Date Filing Date
TR97/00723T TR199700723T1 (xx) 1995-02-01 1996-01-29 Uyu�turucu (ila�) ba��ml�l���ndan zarar g�ren hastalar�n tedavisi i�in melatonin kullan�m�.

Country Status (22)

Country Link
JP (1) JP4516159B2 (fr)
CN (1) CN1083263C (fr)
AT (1) AT408188B (fr)
AU (1) AU695366B2 (fr)
BG (1) BG62876B1 (fr)
BR (1) BR9607169A (fr)
CZ (1) CZ291349B6 (fr)
DK (1) DK176081B1 (fr)
EE (1) EE03384B1 (fr)
FI (1) FI119586B (fr)
IS (1) IS1980B (fr)
LU (1) LU90118B1 (fr)
LV (1) LV11940B (fr)
MD (1) MD1716C2 (fr)
NO (1) NO312814B1 (fr)
NZ (1) NZ298878A (fr)
PL (1) PL183148B1 (fr)
SI (1) SI9620022A (fr)
SK (1) SK284521B6 (fr)
TR (1) TR199700723T1 (fr)
TW (1) TW483757B (fr)
WO (1) WO1996023496A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1272177B1 (fr) 2000-01-05 2007-04-11 Neurim Pharmaceuticals (1991) Limited Methode et formulation permettant de traiter une resistance aux antihypertenseurs et des affections associees
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR102317399B1 (ko) 2012-01-26 2021-10-26 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
CN105142630A (zh) 2012-12-18 2015-12-09 万达制药公司 昼夜节律紊乱的治疗
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
EP3777842A1 (fr) * 2016-10-31 2021-02-17 Neurim Pharmaceuticals Ltd. Mini-comprimés de mélatonine et leur procédé de fabrication

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2134789T3 (es) * 1991-05-09 1999-10-16 Neurim Pharma 1991 Composiciones que contienen melatonina.
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico

Also Published As

Publication number Publication date
IS1980B (is) 2005-01-14
LU90118B1 (fr) 1997-11-13
CZ240597A3 (cs) 1998-01-14
MD1716C2 (ro) 2002-02-28
AU4457496A (en) 1996-08-21
DK89697A (da) 1997-07-30
BG101803A (en) 1998-04-30
AU695366B2 (en) 1998-08-13
DK176081B1 (da) 2006-04-18
CN1083263C (zh) 2002-04-24
PL183148B1 (pl) 2002-05-31
SI9620022A (sl) 1998-10-31
BR9607169A (pt) 1997-11-11
MD1716B2 (en) 2001-08-31
NO973531L (no) 1997-09-30
AT408188B (de) 2001-09-25
BG62876B1 (bg) 2000-10-31
PL321630A1 (en) 1997-12-08
NO973531D0 (no) 1997-07-31
SK103097A3 (en) 1998-01-14
JPH10513177A (ja) 1998-12-15
EE03384B1 (et) 2001-04-16
CN1172431A (zh) 1998-02-04
LV11940A (lv) 1998-01-20
NZ298878A (en) 1999-05-28
CZ291349B6 (cs) 2003-02-12
MD970254A (en) 1999-05-31
JP4516159B2 (ja) 2010-08-04
MX9705856A (es) 1998-07-31
FI119586B (fi) 2009-01-15
ATA901396A (de) 2001-02-15
LV11940B (en) 1998-05-20
NO312814B1 (no) 2002-07-08
TW483757B (en) 2002-04-21
FI973185A (fi) 1997-09-30
SK284521B6 (sk) 2005-05-05
WO1996023496A1 (fr) 1996-08-08
FI973185A0 (fi) 1997-07-31
EE9700166A (et) 1998-02-16
IS4532A (is) 1997-07-25

Similar Documents

Publication Publication Date Title
MEYER et al. Optimizing metoclopramide control of cisplatin-induced emesis
Power et al. Controlled study of withdrawal symptoms and rebound anxiety after six week course of diazepam for generalised anxiety.
McMillan et al. Outcome of renal replacement treatment in patients with diabetes mellitus.
TR199900413T2 (xx) �laca diren�li streptokoklar�n neden oldu�u pn�moni (pn�mokok) tedavisi i�in bir ila� yap�m�nda bir amoksisilin ve klavulanat kombinasyonunun kullan�m�.
DE69804974T2 (de) Opioid-konjugate mit endogenen trägerproteinen
TR199700723T1 (xx) Uyu�turucu (ila�) ba��ml�l���ndan zarar g�ren hastalar�n tedavisi i�in melatonin kullan�m�.
Finland et al. Oral penicillin
Dressman et al. Absorption of flurbiprofen in the fed and fasted states
ES2139842T3 (es) Uso de la melatonina para tratar a pacientes que sufren drogodependencia.
Pier et al. Chronic graft versus host disease presenting with polymyositis.
WALLIN et al. Cimetidine and effect of warfarin
Pearlstein et al. Sumatriptan-associated myocardial infarction: report of case with attention to potential risk factors
NZ284914A (en) use of anti-arthritogenic peptide antibodies, nonadsorbable antibiotic or benign bacteria to treat rheumatoid arthritis by enteral administration
AL-KAWAS et al. Cimetidine and agranulocytosis
Mascioli et al. Characteristics of participants at baseline in the Treatment of Mild Hypertension Study (TOMHS)
LUK et al. Cimetidine and impaired renal function
Abate et al. Effect of naproxen and sulindac on blood pressure response to atenolol
SlNKOVICS et al. Eikenella corrodens as pathogen
Lawson et al. Amoxycillin: Pharmacokinetic studies in normal subjects, patients with pernicious anaemia and those with renal failure
KR950703958A (ko) Hiv 감염증을 치료하기 위한,다른 비뉴클레오사이드 역 전사효소 억제제와 혼합된 bhap 화합물의 용도(use of bhap compounds in combination with other non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infection)
GAROFALO et al. Zinc deficiency and intestinal bypass procedures
Davies et al. Fenclofenac in osteoarthrosis
Hughes Deficiency Patterns in Metallic Poisoning
Gallant Antidepressant overdose: symptoms and treatment
REIMER et al. Acute nonlymphocytic leukemia